Press "Enter" to skip to content

Tag: palivizumab

Ontario to expand RSV vaccine availability for seniors 75 and older this fall

Beginning this fall, all Ontarians 75 and older will be eligible for a free shot that protects against respiratory syncytial virus.

Ontario Health Minister Sylvia Jones is scheduled to announce the expansion of public coverage for RSV vaccines on Wednesday, according to a Ministry of Health release that The Globe and Mail obtained in advance.

Until now, the Ontario government only paid for the RSV vaccine for seniors who were 60 and older and considered high risk, such as transplant recipients, dialysis patients and nursing home residents.

Comments closed

New antibody treatment for RSV in infants highly effective in reducing hospitalisations

A new antibody treatment could reduce by 80 per cent the numbers of babies and young children admitted to hospital with respiratory syncytial virus (RSV), a “groundbreaking” study has found.

Published in the New England Journal of Medicine on Thursday, the study involved 8,058 healthy babies aged up to 12 months from the UK, France and Germany, who were approaching their first RSV season. Half were randomly assigned to receive the antibody nirsevimab by injection, while 4,021 babies received standard care.

Of the babies who received the treatment, only 11 (0.3 per cent) were hospitalised, in comparison with the 60 babies (1.5 per cent) who were hospitalised after receiving just the standard care.

Comments closed